Cholangiocarcinoma (CCA)- Market Insights, Epidemiology and Market Forecast - 2028

Cholangiocarcinoma (CCA)- Market Insights, Epidemiology and Market Forecast - 2028

  • Pages: 210
  • Geography: Global
  • Delivery Timeline: 7-10 Business days
  • Publication: Feb, 2019
  • SKU: DIMI0501
  • Single User License
    20% Off
    $5000
  • Site License
    30% Off
    $8750
  • Glabal License
    $18750
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

Cholangiocarcinoma Market Research Report | CCA Market Report

Cholangiocarcinoma overview

Cholangiocarcinoma is a rare and heterogeneous malignant neoplasm with epithelial cell origin of biliary duct and histologic and biochemical features of cholangiocyte differentiation. The malignant tumor may arise from any portion of the bile duct i.e., from terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural). Inflammation, cholestasis and receptor tyrosine kinases such as IL-6 receptor, c-MET and the EGFR family members are key signaling pathways in cholangiocarcinogenesis.

Cholangiocarcinoma can be classified anatomically based on tumor location within the biliary tree into intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) cholangiocarcinoma subtypes. The latter two subtypes were previously grouped as extrahepatic CCA (eCCA) but are now considered distinct entities based upon differences in their tumor biology and management. 

According to the ICD 10 classification of the disease, Cholangiocarcinoma is coded as intrahepatic bile duct carcinoma (C22.1), extrahepatic bile duct carcinoma (C24.0), Ampulla of Vater (C24.1), overlapping lesion of biliary tract (C24.8) (includes malignant neoplasm of biliary tract whose point of origin cannot be classified to any one of the categories); or it involves both intrahepatic and extrahepatic bile ducts (C22.0-C24.1), and Biliary tract unspecified (C24.9).

DelveInsight's "Cholangiocarcinoma Market Insights, Epidemiology and Market Forecast 2028" report provides the detailed overview of the Cholangiocarcinoma market research and in depth understanding of historical and forecasted Cholangiocarcinoma epidemiology. It highlights the existing Cholangiocarcinoma treatment patterns, potential emerging drugs and also recognises the best of the market opportunities by proffering the current and forecasted Cholangiocarcinoma market revenue, sales trends, and drug uptake during the study period from 2017-2028.

Cholangiocarcinoma Epidemiology 

  1. Cholangiocarcinoma total diagnosed incident population in the 7MM was 18,470 in 2017.
  2. Among all the countries, the estimates show higher Cholangiocarcinoma incidence in the United States with 6,768 cases in 2017.
  3. Among the EU5 countries, Germany had the highest Cholangiocarcinoma incident population with 4,471 cases, followed by Italy and the United Kingdom. Whereas, Spain had the lowest Cholangiocarcinoma incident population. Also, Japan had 4,287 Cholangiocarcinoma incident cases in 2017.

The Cholangiocarcinoma epidemiology report section has all possible division to give a better understanding about the Cholangiocarcinoma market scenario in 7MM. It also helps to recognize the Cholangiocarcinoma causes of exisiting and forecasted trends by investigating the numerous studies, survey reports and key opinion leaders views. The Cholangiocarcinoma report also proffers total diagnosed incident population, incident population, overall incidence, Type-Specific Diagnosed Incident cases, Gender-Specific Diagnosed Incident Cases, Biomarker Specific Diagnosed Incident Cases and Age Specific Diagnosed Incident Cases.

Cholangiocarcinoma Understanding and Treatment Algorithm 

The Cholangiocarcinoma report provides the in-depth analysis of the disease overview by providing details such as disease definition, classification, Cholangiocarcinoma symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about Cholangiocarcinoma treatment algorithms and Cholangiocarcinoma treatment guidelines in the US, Europe, and Japan are also provided in the report.

Cholangiocarcinoma market outlook

  1. Cholangiocarcinoma market size in the 7MM was found to USD 379.57 million in 2017 for the study period (2017-2028). Among 7MM, United States accounts for the highest Cholangiocarcinoma market size in comparison with EU5 and Japan.
  2. In EU5, the Cholangiocarcinoma market size in Germany was found to be highest with USD 82.46 million in 2017, whereas the Spain has the lowest Cholangiocarcinoma market share with USD 3.69 million in 2017. However, the Cholangiocarcinoma market size in Japan was found to be USD 96.73 million in 2017.

The Cholangiocarcinoma market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the Cholangiocarcinoma market trend of each marketed drug and late-stage pipeline drugs. 

The key players that are developing Cholangiocarcinoma drugs are:-

  • Agios Pharmaceuticals
  • Incyte Corporation
  • Delcath Systems
  • Sirtex Medical
  • Jiangsu HengRui Medicine

And many others

Cholangiocarcinoma Market Share by Therapies

This section targets on the rate of uptake of the potential drugs recently driven or will be launched in the Cholangiocarcinoma market during the study period from 2016-2028. The analysis covers Cholangiocarcinoma drug uptake market; Cholangiocarcinoma patients uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of Cholangiocarcinoma market share and Cholangiocarcinoma market size. This evaluation helps in investigating factors important in Cholangiocarcinoma market uptake and in making financial as well as regulatory decisions. 

The drugs like AG-120 (Agios Pharmaceuticals), Pemigatinib (Incyte Corporation), Melphalan /HDS (Delcath Systems), Cisplatin-gemcitabine (Sirtex Medical), Apatinib (Jiangsu HengRui Medicine), etc. along with other compelling Cholangiocarcinoma treatment options in the clinical trials are expected to increase the overall Cholangiocarcinoma drug market in the upcoming years. 

Key Benefits of Cholangiocarcinoma Report 

  • DelveInsight’s report will help to develop Business Strategies by understanding the trends shaping and driving the Cholangiocarcinoma market.
  • Organize sales and marketing efforts by recognising the best opportunities for Cholangiocarcinoma market.
  • To comprehend the future market competition in the Cholangiocarcinoma market.
  • Identify emerging players with potentially dominant product portfolios and create effective counter-strategies to garner a competitive advantage. 

Cholangiocarcinoma Report Insights

  • Cholangiocarcinoma epidemiology segmented by male and female 
  • Cholangiocarcinoma classification
  • Therapeutic Approaches in Cholangiocarcinoma 
  • Cholangiocarcinoma Pipeline Analysis
  • Cholangiocarcinoma Market Size and Trends
  • Cholangiocarcinoma Market Opportunities
  • Impact of upcoming Therapies in Cholangiocarcinoma  

Cholangiocarcinoma Report Key Strengths

  • 10 Year Forecast (2017-2028)
  • 7MM Coverage (The United States; EU5- Germany, France, Italy, Spain and United Kingdom; and Japan)
  • Historical and forecasted Epidemiology 
  • Age specific segmentation and gender specific segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition 

1 Key Insights
2 Cholangiocarcinoma (CCA): Market Overview at a Glance
2.1 Total Market Share (%) Distribution of Cholangiocarcinoma (CCA) in 2017
2.2 Total Market Share (%) Distribution of Cholangiocarcinoma (CCA) in 2028
3 Cholangiocarcinoma (CCA): Disease Background and Overview
3.1 Introduction
3.2 Classification
3.3 Staging
3.3.1 Intrahepatic CCA (iCCA)
3.3.2 Perihilar CCA
3.3.3 Distal extrahepatic
3.4 Symptoms
3.5 Etiology
3.6 Pathogenesis
3.7 Biomarkers
3.8 Diagnosis
3.8.1 Differential diagnosis
3.8.2 Diagnosis of Intrahepatic CCA
3.8.3 Perihilar and distal CCA
3.8.4 Diagnostic Recommendations - British Society of Gastroenterology guidelines
3.8.5 Guidelines for the diagnosis of intrahepatic cholangiocarcinoma
4 Epidemiology and Patient Population
4.1 Key Findings
5 Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in 7MM
6 United States Epidemiology
6.1 Assumptions and Rationale
6.2 Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the United States
6.3 Type– Specific Diagnosed Incident Cases of Cholangiocarcinoma in the United States
6.4 Gender Specific Diagnosed Incident Cases of Cholangiocarcinoma in the United States
6.5 Stage Specific Diagnosed Incident Cases of Intrahepatic Cholangiocarcinoma in the United States
6.6 Stage Specific Diagnosed Incident Cases of Extrahepatic Cholangiocarcinoma in the United States
6.7 Biomarker Specific Diagnosed Incident Cases of Cholangiocarcinoma in the United States
6.8 Age Specific Diagnosed Incident Cases of Cholangiocarcinoma in the United States
7 EU5 Epidemiology
7.1 Germany Epidemiology
7.1.1 Assumptions and Rationale
7.1.2 Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany
7.1.3 Type– Specific Diagnosed Incident Cases of Cholangiocarcinoma in Germany
7.1.4 Gender Specific Incident Cases of Cholangiocarcinoma in Germany
7.1.5 Stage Specific Diagnosed Incident Cases of Intrahepatic Cholangiocarcinoma in Germany
7.1.6 Stage Specific Diagnosed Incident Cases of Extrahepatic Cholangiocarcinoma in Germany
7.1.7 Biomarker Specific Diagnosed Incident Cases of Cholangiocarcinoma in Germany
7.1.8 Age Specific Diagnosed Incident Cases of Cholangiocarcinoma in Germany
7.2 France Epidemiology
7.2.1 Assumptions and rationale
7.2.2 Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France
7.2.3 Type– Specific Diagnosed Incident Cases of Cholangiocarcinoma in the France
7.2.4 Gender Specific Incident Cases of Cholangiocarcinoma in France
7.2.5 Stage Specific Diagnosed Incident Cases of Intrahepatic Cholangiocarcinoma in France
7.2.6 Stage Specific Diagnosed Incident Cases of Extrahepatic Cholangiocarcinoma in France
7.2.7 Biomarker Specific Diagnosed Incident Cases of Cholangiocarcinoma in France
7.2.8 Age Specific Diagnosed Incident Cases of Cholangiocarcinoma in France
7.3 Italy Epidemiology
7.3.1 Assumptions and Rationale
7.3.2 Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy
7.3.3 Type– Specific Diagnosed Incident Cases of Cholangiocarcinoma in Italy
7.3.4 Gender Specific Incident Cases of Cholangiocarcinoma in Italy
7.3.5 Stage Specific Diagnosed Incident Cases of Intrahepatic Cholangiocarcinoma in Italy
7.3.6 Stage Specific Diagnosed Incident Cases of Extrahepatic Cholangiocarcinoma in Italy
7.3.7 Biomarker Specific Diagnosed Incident Cases of Cholangiocarcinoma in Italy
7.3.8 Age Specific Diagnosed Incident Cases of Cholangiocarcinoma in Italy
7.4 Spain Epidemiology
7.4.1 Assumptions and Rationale
7.4.2 Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain
7.4.3 Type– Specific Diagnosed Incident Cases of Cholangiocarcinoma in Spain
7.4.4 Gender Specific Incident Cases of Cholangiocarcinoma in Spain
7.4.5 Stage Specific Diagnosed Incident Cases of Intrahepatic Cholangiocarcinoma in Spain
7.4.6 Stage Specific Diagnosed Incident Cases of Extrahepatic Cholangiocarcinoma in Spain
7.4.7 Biomarker Specific Diagnosed Incident Cases of Cholangiocarcinoma in Spain
7.4.8 Age Specific Diagnosed Incident Cases of Cholangiocarcinoma in Spain
7.5 United Kingdom Epidemiology
7.5.1 Assumptions and Rationale
7.5.2 Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the United Kingdom
7.5.3 Type– Specific Diagnosed Incident Cases of Cholangiocarcinoma in the United Kingdom
7.5.4 Gender Specific Incident Cases of Cholangiocarcinoma in the United Kingdom
7.5.5 Stage Specific Diagnosed Incident Cases of Intrahepatic Cholangiocarcinoma in the UK
7.5.6 Stage Specific Diagnosed Incident Cases of Extrahepatic Cholangiocarcinoma in the UK
7.5.7 Biomarker Specific Diagnosed Incident Cases of Cholangiocarcinoma in the United Kingdom
7.5.8 Age Specific Diagnosed Incident Cases of Cholangiocarcinoma in the United Kingdom
8 Japan Epidemiology
8.1 Assumptions and Rationale
8.2 Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan
8.3 Type– Specific Diagnosed Incident Cases of Cholangiocarcinoma in Japan
8.4 Gender Specific Incident Cases of Cholangiocarcinoma in Japan
8.5 Stage Specific Diagnosed Incident Cases of Intrahepatic Cholangiocarcinoma in Japan
8.6 Stage Specific Diagnosed Incident Cases of Extrahepatic Cholangiocarcinoma in Japan
8.7 Biomarker Specific Diagnosed Incident Cases of Cholangiocarcinoma in Japan
8.8 Age Specific Diagnosed Incident Cases of Cholangiocarcinoma in Japan
9 Therapies and Treatment strategies
9.1.1 Treatment Recommendations – British Society of Gastroenterology guidelines
9.1.2 Guidelines for the Treatment of intrahepatic cholangiocarcinoma
9.2 Treatment Algorithm
10 Unmet Needs
11 Emerging Therapies
11.1 Key Cross Competition
11.2 Ivosidenib: Agios Pharmaceuticals
11.2.1 Product Description
11.2.2 Other Developmental Activities
11.2.3 Clinical Development
11.2.4 Safety and Efficacy
11.2.5 Product Profile
11.3 Pemigatinib: Incyte Corporation
11.3.1 Drug Description
11.3.2 Other Developmental Activities
11.3.3 Clinical Development
11.3.4 Safety and Efficacy
11.3.5 Product Profile
11.4 Infigratinib: QED Therapeutics
11.4.1 Drug Description
11.4.2 Other Developmental Activities
11.4.3 Clinical Development
11.4.4 Safety and Efficacy
11.4.5 Product Profile
11.5 Melphalan: Delcath Systems
11.5.1 Drug Description
11.5.2 Other Developmental Activities
11.5.3 Clinical Development
11.5.4 Safety and Efficacy
11.5.5 Product Profile
11.6 Derazantinib: Basilea Pharmaceutica
11.6.1 Drug Description
11.6.2 Other Developmental Activities
11.6.3 Clinical Development
11.6.4 Safety and Efficacy
11.6.5 Product Profile
11.7 Regorafenib: Bayer
11.7.1 Drug Description
11.7.2 Clinical Development
11.7.3 Safety and Efficacy
11.7.4 Product Profile
11.8 Larotrectinib: Loxo Oncology/ Bayer
11.8.1 Drug Description
11.8.2 Other Developmental Activities
11.8.3 Clinical Development
11.8.4 Safety and Efficacy
11.8.5 Product Profile
11.9 Entrectinib: Roche
11.9.1 Product Description
11.9.2 Other Developmental Activities
11.9.3 Clinical Development
11.9.4 Safety and Efficacy
11.9.5 Product Profile
11.1 Erdafitinib: Janssen Pharmaceutical
11.10.1 Product Description
11.10.2 Other Developmental Activities
11.10.3 Clinical Development
11.10.4 Safety and Efficacy
11.10.5 Product Profile
12 Cholangiocarcinoma (CCA): 7MM Market Analysis
12.1 Key Findings
12.1 Market Size of Cholangiocarcinoma (CCA) in 7MM
13 United States: Market Outlook
13.1 United States Market Size
13.1.1 Total Market size of Cholangiocarcinoma (CCA)
13.1.2 Market Size of Cholangiocarcinoma (CCA) by Therapies in the US
14 EU-5 countries: Market Outlook
14.1 Germany Market Size
14.1.1 Total Market size of Cholangiocarcinoma (CCA)
14.1.2 Market Size of Cholangiocarcinoma (CCA) by Therapies in Germany
14.2 France Market Size
14.2.1 Total Market size of Cholangiocarcinoma (CCA)
14.2.2 Market Size of Cholangiocarcinoma (CCA) by Therapies in France
14.3 Italy Market Size
14.3.1 Total Market size of Cholangiocarcinoma (CCA)
14.3.2 Market Size of Cholangiocarcinoma (CCA) by Therapies in Italy
14.4 Spain Market Size
14.4.1 Total Market size of Cholangiocarcinoma (CCA)
14.4.2 Market Size of Cholangiocarcinoma (CCA) by Therapies in Spain
14.5 United Kingdom Market Size
14.5.1 Total Market size of Cholangiocarcinoma (CCA)
14.5.2 Market Size of Cholangiocarcinoma (CCA) by Therapies in the UK
15 Japan Market Outlook
15.1 Japan Market Size
15.1.1 Total Market size of Cholangiocarcinoma (CCA)
15.1.2 Market Size of Cholangiocarcinoma (CCA) by Therapies in Japan
16 Market Drivers
17 Market Barriers
18 Appendix
18.1 Report Methodology
19 DelveInsight Capabilities
20 Disclaimer
21 About DelveInsight

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-S